HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Charkit builds natural ingredient offering

This article was originally published in The Rose Sheet

Executive Summary

Charkit Chemical Corporation announces distribution agreement with CRM International that gives it access to CRM's Plantec ingredients, many of which are certified organic by French firm Ecocert and offer a range of opportunities for personal-care formulation, according to Sept. 23 release. Plantec vegetable butters are ideal for lipsticks, face creams and cosmeceutical makeup, Charkit says. Plantec Blackcurrant Butter provides "heavy, rich texture as well as the sought-after anti-aging effect especially suited to night creams and products for very dry skin," firm adds, while Plantec Silk Olea Wax can serve a key role in sun-care products. "We encourage inquiries about CRM's distinctive ingredients and can provide personal-care and cosmetic manufacturers with the assistance needed in the formulation and reformulation of products," Charles Hinnant, president of Charkit, says

You may also be interested in...



Switzerland Provides Gateway Into Mainland Europe For BASF’s Hepacor

With the Swiss launch of its Non-Alcoholic Fatty Liver Disease supplement, BASF is looking to make inroads into continental Europe. 

Orchard’s Gene Therapy Under Fast-Track Review At EMA

A handful of new products are under review at the European Medicines Agency. Orchard Therapeutics' gene therapy application will be fast-tracked; Roche's filing for its new flu treatment will not.

Ipsen’s Palovarotene Hit By FDA Clinical Hold

The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.

UsernamePublicRestriction

Register

RS015684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel